AsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107
BALTIMORE, July 26, 2023 (GLOBE NEWSWIRE) -- AsclepiX Therapeutics, Inc., a clinical-stage biotech company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases,…